One of the many challenging aspects of therapy with warfarin is its variable pharmacokinetics. A major termination of warfarin metabolism is the CYP2C9 liver enzyme and its metabolism of S-warfarin.

A new study in the British Journal of Clinical Pharmacology sought to assess pharmacodynamic changes during transition from rivaroxaban, a selective direct Factor Xa inhibitor, to warfarin in ...

During capecitabine treatment, the area under the plasma concentration time curve from 0 to infinity (AUC 0-∞) of S -warfarin increased by 57% (90% CI, 32% to 88%) with a 51% prolongation of the ...

The Company's Phase 1 trial was a US multi-center, double-blind, randomized, crossover study designed to evaluate the safety, tolerability, and pharmacokinetics of tecarfarin and of warfarin in 12 ...

[The author responds:] I thank Nizam Ahmed for his suggestion. Although the goal of Table 1 in my article 1 was not comprehensiveness, anticonvulsants can indeed alter the pharmacokinetics of warfarin ...

Investigators assessed pharmacokinetics and pharmacodynamics of the pharmacologically active metabolite, designating a confidence interval (CI) for the "no-effect" boundary of 0.80 to 1.25 for ...

Pharmacology Warfarin works to decrease blood coagulation and, therefore, lower the risk of thrombosis and embolism, by inhibiting the enzyme that is responsible for the oxidation of vitamin K in ...

Results During capecitabine treatment, the area under the plasma concentration time curve from 0 to infinity (AUC 0-∞) of S -warfarin increased by 57% (90% CI, 32% to 88%) with a 51% prolongation of ...

Finally, warfarin may also be used to aid in the prevention of systemic embolism in mechanical heart valves, as these are prone to develop thrombosis. While this treatment is beneficial for the ...